Fluvoxamine Reduces Fatigue in Long COVID, Trial Reports

A randomized, placebo-controlled adaptive trial in Brazil tested fluvoxamine and metformin for fatigue in 399 adults with long COVID. The trial reported that fluvoxamine produced a statistically meaningful reduction in Fatigue Severity Scale scores at 60 and 90 days and improved quality-of-life scores, with fewer adverse events than placebo or metformin, while findings for metformin were inconclusive due to a dose change and early termination of that arm.

Most relevant for: Adults with persistent fatigue 3 to 24 months after confirmed SARS-CoV-2 infection managed in outpatient settings.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.